H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Genocea Biosciences (GNCA) today and set a price target of $32. The company’s shares opened today at $3.70, close to its 52-week low of $2.24.
Pantginis observed:
“Valuation and risks to price target achievement. We reiterate our Buy rating and are lowering our price target to $32 from $42 to reflect the recent dilution, and fully diluted share count from the company’s equity raise.”
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -9.0% and a 32.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
Genocea Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $23.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.28 and a one-year low of $2.24. Currently, Genocea Biosciences has an average volume of 928K.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GNCA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses.
